DN
Therapeutic Areas
Torqur Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Bimiralisib (PQR309) | Actinic Keratosis | Phase 2 |
| Next-gen PI3K/mTOR inhibitors | Oncology | Pre-clinical |
Leadership Team at Torqur
PD
Prof. Dr. Michael N. Hall
Chairman and Non-Executive Board Member
DV
Dr. Vladimir Cmiljanovic
Vice-Chairman and Executive Board Member
DJ
Dr. Jeanette Wood
Non-Executive Board Member
DT
Dr. Thomas Ladner
Non-Executive Board Member & Secretary
CT
Christoph Tschumi
Non-Executive Board Member